NeuroSense Therapeutics has filed a prospectus supplement with the Securities and Exchange Commission on June 27, 2024, updating and amending its previous prospectus dated April 8, 2024. The supplement pertains to the offering of 3,000,000 ordinary shares and warrants to purchase up to an additional 3,000,000 ordinary shares. The company's ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW', respectively. On June 26, 2024, the closing prices were $0.85 for ordinary shares and $0.18 for warrants. The supplement includes information from the company's Report on Form 6-K, which details amendments to certain warrants issued to an institutional investor. These amendments extend the termination date of warrants issued in June 2023 and April 2024 to October 12, 2029, and make adjustments to the 'Redemption Right' of the...Show More

NeuroSense Therapeutics has filed a prospectus supplement with the Securities and Exchange Commission on June 27, 2024, updating and amending its previous prospectus dated April 8, 2024. The supplement pertains to the offering of 3,000,000 ordinary shares and warrants to purchase up to an additional 3,000,000 ordinary shares. The company's ordinary shares and warrants are traded on the Nasdaq under the symbols 'NRSN' and 'NRSNW', respectively. On June 26, 2024, the closing prices were $0.85 for ordinary shares and $0.18 for warrants. The supplement includes information from the company's Report on Form 6-K, which details amendments to certain warrants issued to an institutional investor. These amendments extend the termination date of warrants issued in June 2023 and April 2024 to October 12, 2029, and make adjustments to the 'Redemption Right' of the 2023 Warrant. The company emphasizes the high degree of risk involved in investing in its securities and refers to the 'Risk Factors' section of the original prospectus for further details. The filing of this prospectus supplement is also incorporated by reference into the company's existing registration statements on Form S-8 and Form F-3.